Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
0
Authors
Paul Chapman
Paul Chapman•Jean‐Jacques Grob•Grant McArthur
Published
June 5, 2011
Abstract
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.
